PPD, Inc. (PPD) Prices 38M Share Secondary Offering at $32.25M/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
PPD Inc. (PPD) PT Raised to $37 at Credit Suisse, Following Earnings
September 15, 2020 1:28 PM EDTCredit Suisse analyst Erin Wilson Wright raised the price target on PPD Inc. (NASDAQ: PPD) to $37.00 (from $35.00) while maintaining a Outperform rating.
... MorePre-Open Stock Movers 09/15: (MRNS) (IPOB) (FCAU) Higher; (NKLA) (PPD) (LEN) Lower (more...)
September 15, 2020 9:30 AM EDTPre-Open Stock Stock Movers
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) 61% HIGHER; announced positive top-line results from its registrational Phase 3 clinical trial (Marigold Study) evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures.
Social Capital Hedosophia Holdings Corp. II (NYSE:... More
PPD Inc. (PPD) PT Raised to $37 at KeyBanc
September 15, 2020 5:52 AM EDTKeyBanc analyst Donald Hooker raised the price target on PPD Inc. (NASDAQ: PPD) to $37.00 (from $35.00) while maintaining a Overweight rating.... More
